Diverticulitis Disease Market Size Worth $3.86 Billion by 2032 | CAGR: 8.91%

Diverticulitis Disease Market Size Worth $3.86 Billion by 2032 | CAGR: 8.91%

The global diverticulitis disease market size is expected to reach USD 3.86 billion by 2032, according to a new study by Polaris market research. The report “Diverticular Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Uncomplicated, Complicated); By Treatment; By End-User; By Region; Segment Forecast, 2023-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rise in the elderly population causes a rise in the patient population, which in turn increases the market for diverticular illness. The worldwide market has therefore forecast the demand for medications for improved treatment. It has been primarily fueled by the rising demand for cutting-edge medical care, the rise in cigarette smoking, and the broad movement of young people toward sedentary lifestyles. For instance, West Virginia had the highest smoking rate in the United States in 2022, with a rate of 23.8%, according to the CDC's 2022 report. The leading cause of the preventable disease & recorded substantial deaths in the U.S alone, smoking accounts for almost 500,000 480,000 deaths annually. However, the CDC predicted that 30.8 million Americans or 12.5% of adults smoked cigarettes in 2020.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/diverticulitis-disease-market/request-for-sample

Diverticulosis and diverticular disease of the colon are becoming more common worldwide. Despite the fact that the majority of patients stay asymptomatic for a very long time, diverticular illness of the colon, particularly acute diverticulitis, is quite common and is beginning to put a large financial strain on national health systems. For instance, a research paper by Alexander T. Hawkins, published in 2022, states that diverticulosis of the sigmoid colon affects about 33% of people over the age of 60 and is frequent in the industrialized world. Diverticulitis could occur in up to 15% of these patients at some time in their lives.

The current emphasis is on determining the best therapy strategy through the testing of numerous treatments. Unfortunately, there is still a lack of solid data supporting the efficacy of a medicinal approach to preventing a recurrence of acute diverticulitis. Here, we give a succinct overview of these treatments' efficacy and prospects for the future.

Diverticular Disease Market Report Highlights

  • Uncomplicated will dominate the market in 2022, accounting for major sales. The primary reason for the market's expansion is the ongoing advancement in antibiotic treatment research.
  • In 2022, medications will rule the market. Since the primary element driving market growth is the use of antibiotics to treat infections that may arise in acute diverticulitis, the category benefits from this.
  • In 2022, hospitals made up the greatest revenue portion of the market. The key driver of market growth is the presence of experts in hospitals who can guide patients in selecting appropriate tests.
  • North America will produce majority of global income in 2022. Over the course of the forecast period, the market is predicted to gain from elements including the growing senior population and expanding public awareness of local health issues.
  • The global players with global presence include Sucampo Pharmaceuticals, Valeant Pharmaceuticals International, Synergy Pharmaceuticals, Ardelyx, Astellas Pharma, Novartis AG, Hikma Pharmaceuticals and Baxter International.

Polaris Market Research has segmented the Diverticular Disease Market report based on type, treatment, end-user and region:

Diverticular Disease, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Uncomplicated
  • Complicated

Diverticular Disease, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Medications
  • Surgery
  • Supportive care
  • Penicillin Antibiotic
  • Antibiotics
  • Dietary Supplements
  • IV fluids

Diverticular Disease, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Specialty centers
  • Hospitals
  • Research centers

Diverticular Disease, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa